Comparison of Survival and Quality of Life in Advanced Non–Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial

摘要: PURPOSE: Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non–small-cell lung cancer (NSCLC). To determine whether new agent, paclitaxel, would further improve NSCLC, the Eastern Cooperative Oncology Group conducted randomized trial comparing paclitaxel plus cisplatin to standard regimen consisting of and etoposide. PATIENTS AND METHODS: The study was carried out by multi-institutional cooperative group chemotherapy-naive stage IIIB IV NSCLC patients receive or etoposide cisplatin. Paclitaxel administered at two different dose levels (135 mg/m2 250 mg/m2), given 100 daily on days 1 3. Each repeated every 21 each included (75 mg/m2). RESULTS: characteristics 599 were well-balanced across three treatment groups. Superior observed w...